Anavex Life Sciences Corp (AVXL)

[F1ash]

Im curious as to what others think why we didn't start 3? Missling being dishonest is not a valid answer.

I believe the logical holdup was we submitted more than the FDA was willing to chew ( we submitted both Rett and PD and the FDA said only one and we went with Rett because of the OD status) and the FDA had more questions/concerns that we realized thus no word on trial starting although we did submit the IND.

Let’s run out your suppositions a bit further and see how committed you remain to their likelihood.

Anavex submitted an IND for PD to the FDA and the FDA responded with a denial of the PD IND and Anavex failed to disclose that denial to shareholders? Are you sure you want that to be the case?

Perhaps rather than responding to a written IND request with an actual denial the FDA went outside of their norms and whispered in Anavex’s ear that they would just pretend like they never received the PD IND so that particular information didn’t need to be disclosed and Anavex could go the EU route instead? Seem likely?

Assuming that the PD IND was submitted and rejected because of FDA safety concerns that Anavex has failed to disclose, exactly how likely are they to actually approve A2-73 for administration to fragile little girls who would have difficulty in communicating side effects?


The CEO was not being dishonest.

At the beginning of every single presentation Anavex told you not to believe anything they said about future plans and events until they actually happened. It’s phrased “place undue reliance on”, I believe, but it means basically the same thing for all practical purposes.

If you really want to know why Management probably stated that all three trials would start in 2017 it likely has to do with the investment phrase “Buy the Rumor” imho.

If your a company needing to fund operations by selling new shares via an LPC type ELOC, then wouldn’t the best time to sell be “During the Rumor”.

Didn’t many of the folks here on this board buy more shares because they “Placed undue reliance on” company statements of future events? (All three trials in 2017)

Theories are only as good as their ability to predict real word events imho. To that end, I propose a way to test “my theory”.

Let’s look at the financials.




“Cash and equivalents of $27.4 million at September 30, 2017, compared to $9.2 million at September 30, 2016.

Impressive performance by a CEO, if you ask me, especially if you consider the fact that they burned an extra ~$9 million in cash during that same period.

That’s an amazing performance considering that not one of the promised trials has actually begun yet in 2017. (Handy things those Forward Looking Statement).

And I believe that is actually just “The Tip of the Iceberg”

My theory continues in that I personally believe Dr. M is currently putting a big red bow on a nice Christmas present for all Anavex shareholders.

You see this last filing cut off on September 30th. That’s important because I believe Anavex could not start tapping the newly authorized 5 million shares until they filed the prospectus on September 7th (that date could be off a few days depending on whether the filing of the “effect” or the “prospectus” signals the go ahead to tap LPC.


I predict ,according to my theory, that Anavex actually already has roughly $12 million more in the bank than this filing shows. If the next filing shows $40 million in the bank instead of $27 million, won’t you all be pleased by that and missed deadlines will be forgiven?

I haven’t run the math lately but my theory predicts that Anavex would have around 2 million more shares to go if the theory holds.

Clinical trials are expensive. It’s impossible to fail a trial until you run it.